Maurizio Callari

Another great paper from @caldaslab.bsky.social! TME composition evaluated in 15k breast cancer transcriptomes!

SARS-CoV-2 vaccines sensitize tumors to immune checkpoint blockade Fondazione Gianni Bonadonna

mRNA vaccines targeting non-tumor-related antigens are potent immune modulators capable of sensitizing tumors to immune checkpoint blockade
fondazionebonadonna.org/en/sars-cov-...
#FondazioneBonadonna #Oncology #CancerResearch @mauriziocallari.bsky.social

Having a great time at #EACR2025, catching up and continuing doing exciting science with @carloscaldas1960.bsky.social and @caldaslab.bsky.social!

Afamitresgene autoleucel in advanced synovial sarcoma and myxoid round cell liposarcoma Fondazione Gianni Bonadonna

Afami-cel showed durable responses in heavily pretreated patients with sarcoma, providing a rationale for the treatment of solid tumors with a T-cell receptor therapy
fondazionebonadonna.org/en/afamitres...
#fondazionebonadonna #oncology #CancerResearch
@mauriziocallari.bsky.social

I am excited to share the latest publication from the Nguyen, Caldas @carloscaldas1960.bsky.social and Rueda labs @ruedalab.bsky.social. This was a massive effort from a fantastic team and I’m grateful to everyone on the paper for their work on this project! doi.org/10.1016/j.ce...
#bcsm #PDTX

An ultrasensitive ctDNA detection platform is highly prognostic in early breast cancer - Fondazione Michelangelo Whole genome sequencing-powered ctDNA sequencing improves detection at baseline and follow-up, helping to identify early breast cancer patients at high risk of relapse

Whole genome sequencing-powered ctDNA sequencing improves detection at baseline and follow-up helping to identify early breast cancer patients at high risk of relapse
www.fondazionemichelangelo.org/news-update/...
#FondazioneBonadonna #Oncology #CancerResearch @mauriziocallari.bsky.social

1/n
Fantastic to see this published. Anticipatory genomics demonstration: ctDNA and ML to predict CT progression!
Well done @emmajb001.bsky.social and @mortegaduran.bsky.social! Great collaboration of @caldaslab.bsky.social with @ruedalab.bsky.social!
#DETECT started by @sj-dawson.bsky.social!

Here an overview of our #translational research on samples from the #NAPHER2 trial recently published in #NatComms @natureportfolio.nature.com. We identified #predictive #biomarkers and molecular dynamics in HER2+ER+ #breastcancer receiving chemo-free #targeted #treatment 👇

Thank you for your words! And feel free to reach out for more info

Thank you to all co-authors: Matteo dugo, Marco Barreca, Giampaolo Bianchini, Luca Gianni et al, funding, #AIRC, #BCRF, fondazionemichelangelo.org @fgbonadonna.bsky.social and all patients!

Recent findings from the #PATINA trial further confirmed the efficacy of combined targeted treatment in HER2+ER+ BC. We provide a better understanding of #drivers and #dynamics of HER2+ER+ tumour response, towards to the design of de-escalation or #escalation strategies.

The HighHigh group showed #dysfunctional immune infiltration and overexpression of #therapeutic #targets like #PAK4 at baseline. The LowLow group exhibited a #LuminalA phenotype by the end of treatment

Stratification based on Ki67 at Day14 and at surgery defined three response groups (Ki67 HighHigh, LowHigh, LowLow), with divergent tumour and stroma expression dynamics

We performed #RNAseq and #TIL assessment in serial biopsies from the NA-PHER2 trial. High #immune #infiltration and low #ER signalling at baseline correlated with #pCR, while #TP53 mutations associated with high Day14 #Ki67

HER2+ER+ BC shows lower response to chemo+antiHER2 treatment. #Biomarker-guided alternative approaches could improve #outcomes and reduce #toxicities.
#NAPHER2 trial investigated #neoadjuvant #HER2 blockade and CDK4/6 inhibition with or without #endocrine therapy in HER2+ER+ BC.

Determinants of response and molecular dynamics in HER2+ER+ breast cancers from the NA-PHER2 trial receiving HER2-targeted and endocrine therapies Nature Communications - NA-PHER2 was a neoadjuvant trial of HER2-targeted trastuzumab and pertuzumab plus the CDK4/6 inhibitor palbociclib with or without endocrine therapy in HER2-positive,...

📢 Our work just published in
@naturecomms.bsky.social @natureportfolio.nature.com!
What is driving #response to #targeted #treatments in HER2+ER+ #breastcancer? How is the tumour ecosystem affected by treatment? Find the answers in our paper 👉 rdcu.be/ecbVR
Key points below 👇

Nivolumab and ipilimumab in metastatic colorectal cancer Fondazione Gianni Bonadonna

Nivolumab plus ipilimumab show superior progression-free survival versus nivolumab in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer
fondazionebonadonna.org/en/nivolumab...
#fondazionebonadonna #oncology #CancerResearch
@mauriziocallari.bsky.social

Insights from a Keynote Speaker: Episode 19 of The Cancer Researcher Podcast - The Cancer Researcher Carlos Caldas shares insights into his breast cancer research and the power of patient-derived xenograft models.

Listen to episode 19 of The Cancer Researcher Podcast where @carloscaldas1960.bsky.social shares insights into his breast cancer research, the evolution of cancer science & the power of patient-derived xenograft models ahead of his Keynote Talk at EACR 2025.

magazine.eacr.org/insights-fro...

Just finished a Teams meeting with @mauriziocallari.bsky.social and Oscar Rueda discussing Single Nucleus Sequencing generated by @sc10021.bsky.social from 150 #METABRIC breast cancers, in conjunction with all the other multi-omic data. At #EACR2025 update coming...

#MedSky #OncSky #Altmetrics @cosmocollab.bsky.social @oncoalert.bsky.social

Amazing resource for pre-clinical research in triple-negative breast cancer!

We recently announced a dual new release of intOGen and boostDM

Computational analysis of 33,218 tumor genomes to identify cancer genes and driver mutations

➡️ Compendium of Cancer Driver Genes - www.intogen.org

➡️ In Silico Saturation Mutagenesis of Cancer Genes - www.intogen.org/boostdm

A great piece of work, I'm happy to have contributed to during my time in Cambridge! #PDX #breastcancer #drug #response #prediction

Out today in Nature: "The Human Cell Atlas"! In my News and Views, I compare the cell atlas to early naturalists creating an atlas of South America. Researchers mining this cell atlas can now make big discoveries, just as the next naturalists then discovered evolution.
www.nature.com/articles/d41...

I strongly support this